To provide long term capital appreciation and income.
Name | % Net Assets |
---|---|
Aviva Inv Absolute TAA Fund | 5.0% |
BG Group | 3.0% |
GlaxoSmithKline | 2.6% |
European Investment Bank 4.75% 2012 | 1.9% |
Vodafone Group | 1.5% |
Astrazeneca | 1.4% |
HSBC Holdings PLC (UK Reg) | 1.4% |
KFW Int Finance 5.625% 7/12/2009 | 1.3% |
2¼% Treasury Gilt 2014 | 1.0% |
US Treasury 1.75% 31/03/2014 | 1.0% |
Key | % Net Assets |
---|---|
Aviva Inv Absolute TAA Fund | 5.0% |
BG Group | 3.0% |
GlaxoSmithKline | 2.6% |
European Investment Bank 4.75% 2012 | 1.9% |
Other | 87.5% |
Date | 21-Nov-2024 |
---|---|
NAV | 273.20p |
Currency | GBP |
Change | 0.71p |
% | 0.26% |
YTD change | 15.53p |
YTD % | 6.03% |
Fund Inception | 19/02/2001 |
---|---|
Fund Manager | Peter Michaelis |
TER | 0.42 (31-Jan-2013) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.08 |
You are here: research